Screening for hepatocellular carcinoma in chronic liver disease: A systematic review

Annals of Internal Medicine

Volumn 161, Issue 4, 2014, Pages 261-269

  Kansagara, Devan ^a   Papak, Joel ^a   Pasha, Amirala S ^b   O'Neil, Maya ^a   Freeman, Michele ^a   Relevo, Rose ^a   Quiñones, Ana ^b   Motu'apuaka, Makalapua ^c   Jou, Janice H ^a  

^a PORTLAND VA MEDICAL CENTER   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c Oregon Evidence based Practice Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN;

ADVERSE OUTCOME; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER SCREENING; CANCER STAGING; CHRONIC LIVER DISEASE; COMPARATIVE STUDY; ECHOGRAPHY; HEPATITIS B; HUMAN; LIVER CELL CARCINOMA; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; CARCINOMA, HEPATOCELLULAR; CHRONIC DISEASE; COMPLICATION; EARLY DIAGNOSIS; EVIDENCE BASED MEDICINE; LIVER DISEASE; LIVER NEOPLASMS; MASS SCREENING; MORTALITY; RANDOMIZED CONTROLLED TRIAL (TOPIC);

CARCINOMA, HEPATOCELLULAR; CHRONIC DISEASE; EARLY DETECTION OF CANCER; EVIDENCE-BASED MEDICINE; HUMANS; LIVER DISEASES; LIVER NEOPLASMS; MASS SCREENING; OBSERVATIONAL STUDY AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84907326817     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/M14-0558     Document Type: Review

References (57)

1. Jemal A, Simard EP, Dorell C, Noone AM, Markowitz LE, Kohler B, et al. Annual Report to the Nation on the Status of Cancer, 1975-2009, featuring the burden and trends in human papillomavirus(HPV)-associated cancers and HPV vaccination coverage levels. J Natl Cancer Inst. 2013;105:175-201. [PMID: 23297039]
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10-29. [PMID: 22237781]
3. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol. 2009;27:1485-91. [PMID: 19224838]
4. Singal A, Volk ML, Waljee A, Salgia R, Higgins P, Rogers MA, et al. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther. 2009;30:37-47. [PMID: 19392863]
5. Bruix J, Sherman M; American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53: 1020-2. [PMID: 21374666]
6. Llovet JM, Ducreux M, Lencioni R, Di Bisceglie AM, Galle PR, Dufour JF, et al. EASL-EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma. Eur J Cancer. 2012;48:599-641.
7. Omata M, Lesmana LA, Tateishi R, Chen PJ, Lin SM, Yoshida H, et al. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int. 2010;4:439-74. [PMID: 20827404]
8. Lederle FA, Pocha C. Screening for liver cancer: the rush to judgment. Ann Intern Med. 2012;156:387-9. [PMID: 22393134]
9. Bleyer A, Welch HG. Effect of three decades of screening mammography on breast-cancer incidence. N Engl J Med. 2012;367:1998-2005. [PMID: 23171096]
10. Etzioni R, Penson DF, Legler JM, di Tommaso D, Boer R, Gann PH, et al. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst. 2002;94:981-90. [PMID: 12096083]
11. Aghoram R, Cai P, Dickinson JA. Alpha-foetoprotein and/or liver ultrasonography for screening of hepatocellular carcinoma in patients with chronic hepatitis B. Cochrane Database Syst Rev. 2012;9:CD002799. [PMID: 22972059]
12. Sherman M, Bruix J, Porayko M, Tran T; AASLD Practice Guidelines Committee. Screening for hepatocellular carcinoma: the rationale for the American Association for the Study of Liver Diseases recommendations [Editorial]. Hepatology. 2012;56:793-6. [PMID: 22689409]
13. Kansagara D, Papak J, Pasha AS, O'Neil M, Freeman M, Relevo R, et al. Screening for hepatocellular cancer in chronic liver disease: a systematic review. VA-ESP project no. 05-225. Washington, DC: U.S. Department of Veterans Affairs; 2013.
14. Health Services Research & Development. ESP Reports in Progress. Washington, DC: U.S. Department of Veterans Affairs; 2014. Accessed at www.hsrd.research.va.gov/publications/esp/in-progress.cfm on 19 May 2014.
15. Higgins JPT, Green S, eds. Part 2, Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.10. The Cochrane Collaboration; 2011. Accessed at www.cochrane-handbook.org on 19 May 2014.
16. Guyatt GH, Oxman AD, Schünemann HJ, Tugwell P, Knottnerus A. GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. J Clin Epidemiol. 2011;64:380-2. [PMID: 21185693]
17. Viswanathan M, Ansari MT, Berkman ND, Chang S, Hartling L, McPheeters M, et al. Assessing the Risk of Bias of Individual Studies in Systematic Reviews of Health Care Interventions. Methods Guide for Effectiveness and Comparative Effectiveness Reviews. Rockville, MD: Agency for Healthcare Research and Quality; 2012. [PMID: 22479713]
18. Deeks JJ, Dinnes J, D'Amico R, Sowden AJ, Sakarovitch C, Song F, et al; International Stroke Trial Collaborative Group. Evaluating non-randomised intervention studies. Health Technol Assess. 2003;7:iii-x, 1-173. [PMID: 14499048]
19. Patient-Centered Outcomes Research Institute. PCORI Methodology Standards. Washington, DC: Patient-Centered Outcomes Research Institute; 2012.
20. Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol. 2004;130:417-22. [PMID: 15042359]
21. Chen JG, Parkin DM, Chen QG, Lu JH, Shen QJ, Zhang BC, et al. Screening for liver cancer: results of a randomised controlled trial in Qidong, China. J Med Screen. 2003;10:204-9. [PMID: 14738659]
22. Wang JH, Chang KC, Kee KM, Chen PF, Yen YH, Tseng PL, et al. Hepatocellular carcinoma surveillance at 4- vs. 12-month intervals for patients with chronic viral hepatitis: a randomized study in community. Am J Gastroenterol. 2013;108:416-24. [PMID: 23318478]
23. Trinchet JC, Chaffaut C, Bourcier V, Degos F, Henrion J, Fontaine H, et al; Groupe d'Etude et de Traitement du Carcinome Hépatocellulaire (GRETCH). Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: a randomized trial comparing 3- and 6-month periodicities. Hepatology. 2011;54:1987-97. [PMID: 22144108]
24. Bolondi L, Sofia S, Siringo S, Gaiani S, Casali A, Zironi G, et al. Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis. Gut. 2001;48:251-9. [PMID: 11156649]
25. Chen TH, Chen CJ, Yen MF, Lu SN, Sun CA, Huang GT, et al. Ultrasound screening and risk factors for death from hepatocellular carcinoma in a high risk group in Taiwan. Int J Cancer. 2002;98:257-61. [PMID: 11857416]
26. Davila JA, Weston A, Smalley W, El-Serag HB. Utilization of screening for hepatocellular carcinoma in the United States. J Clin Gastroenterol. 2007;41: 777-82. [PMID: 17700427]
27. El-Serag HB, Kramer JR, Chen GJ, Duan Z, Richardson PA, Davila JA. Effectiveness of AFP and ultrasound tests on hepatocellular carcinoma mortality in HCV-infected patients in the USA. Gut. 2011;60:992-7. [PMID: 21257990]
28. Giannini E, Arzani L, Borro P, Botta F, Fasoli A, Risso D, et al. Does surveillance for hepatocellular carcinoma in HCV cirrhotic patients improve treatment outcome mainly due to better clinical status at diagnosis? Hepatogastroenterology. 2000;47:1395-8. [PMID: 11100360]
29. Kemp W, Pianko S, Nguyen S, Bailey MJ, Roberts SK. Survival in hepatocellular carcinoma: impact of screening and etiology of liver disease. J Gastroenterol Hepatol. 2005;20:873-81. [PMID: 15946134]
30. Kuo YH, Lu SN, Chen CL, Cheng YF, Lin CY, Hung CH, et al. Hepatocellular carcinoma surveillance and appropriate treatment options improve survival for patients with liver cirrhosis. Eur J Cancer. 2010;46:744-51. [PMID: 20060710]
31. Leykum LK, El-Serag HB, Cornell J, Papadopoulos KP. Screening for hepatocellular carcinoma among veterans with hepatitis C on disease stage, treatment received, and survival. Clin Gastroenterol Hepatol. 2007;5:508-12. [PMID: 17382601]
32. Pascual S, Irurzun J, Zapater P, Such J, Sempere L, Carnicer F, et al. Usefulness of surveillance programmes for early diagnosis of hepatocellular carcinoma in clinical practice. Liver Int. 2008;28:682-9. [PMID: 18433394]
33. Tanaka H, Nouso K, Kobashi H, Kobayashi Y, Nakamura S, Miyake Y, et al. Surveillance of hepatocellular carcinoma in patients with hepatitis C virus infection may improve patient survival. Liver Int. 2006;26:543-51. [PMID: 16761998]
34. Taura N, Hamasaki K, Nakao K, Ichikawa T, Nishimura D, Goto T, et al. Clinical benefits of hepatocellular carcinoma surveillance: a single-center, hospital-based study. Oncol Rep. 2005;14:999-1003. [PMID: 16142364]
35. Tong MJ, Sun HE, Hsien C, Lu DS. Surveillance for hepatocellular carcinoma improves survival in Asian-American patients with hepatitis B: results from a community-based clinic. Dig Dis Sci. 2010;55:826-35. [PMID: 19960258]
36. Trevisani F, De Notariis S, Rapaccini G, Farinati F, Benvegnu L, Zoli M, et al; Italian Liver Cancer Group. Semiannual and annual surveillance of cirrhotic patients for hepatocellular carcinoma: effects on cancer stage and patient survival (Italian experience). Am J Gastroenterol. 2002;97:734-44. [PMID: 11922571]
37. Trevisani F, Cantarini MC, Labate AM, De Notariis S, Rapaccini G, Farinati F, et al; Italian Liver Cancer (ITALICA) group. Surveillance for hepatocellular carcinoma in elderly Italian patients with cirrhosis: effects on cancer staging and patient survival. Am J Gastroenterol. 2004;99:1470-6. [PMID: 15307862]
38. Wong GL, Wong VW, Tan GM, Ip KI, Lai WK, Li YW, et al. Surveillance programme for hepatocellular carcinoma improves the survival of patients with chronic viral hepatitis. Liver Int. 2008;28:79-87. [PMID: 17900247]
39. Yu EW, Chie WC, Chen TH. Does screening or surveillance for primary hepatocellular carcinoma with ultrasonography improve the prognosis of patients? Cancer J. 2004;10:317-25. [PMID: 15530261]
40. Gaba RC, Kallwitz ER, Parvinian A, Bui JT, Von Roenn NM, Berkes JL, et al. Imaging surveillance and multidisciplinary review improves curative therapy access and survival in HCC patients. Ann Hepatol. 2013;12:766-73. [PMID: 24018494]
41. Cucchetti A, Trevisani F, Pecorelli A, Erroi V, Farinati F, Ciccarese F, et al; for the Italian Liver Cancer (ITA.LI.CA) group. Estimation of lead-time bias and its impact on the outcome of surveillance for the early diagnosis of hepatocellular carcinoma. J Hepatol. 2014. [PMID: 24717522]
42. Fletcher RH, Fletcher SW, Wagner EH. Clinical Epidemiology. The Essentials. 2nd ed. Baltimore: Williams & Wilkins; 1988.
43. Silva MA, Hegab B, Hyde C, Guo B, Buckels JA, Mirza DF. Needle track seeding following biopsy of liver lesions in the diagnosis of hepatocellular cancer: a systematic review and meta-analysis. Gut. 2008;57:1592-6. [PMID: 18669577]
44. Chou R, Cuevas C, Fu R, Devine B, Wasson N, Ginsburg A, et al. Imaging Techniques for the Diagnosis and Staging of Hepatocellular Carcinoma. Comparative Effectiveness Review No. ###. (Prepared by the Pacific Northwest Evidence-based Practice Center under contract 290-2012-00014i.) AHRQ Publication No. ###. Rockville, MD: Agency for Healthcare Research and Quality. [Forthcoming].
45. Rahman A, Assifi MM, Pedroso FE, Maley WR, Sola JE, Lavu H, et al. Is resection equivalent to transplantation for early cirrhotic patients with hepatocellular carcinoma? A meta-analysis. J Gastrointest Surg. 2012;16:1897-909. [PMID: 22836922]
46. Asiyanbola B, Chang D, Gleisner AL, Nathan H, Choti MA, Schulick RD, et al. Operative mortality after hepatic resection: are literature-based rates broadly applicable? J Gastrointest Surg. 2008;12:842-51. [PMID: 18266046]
47. Izzo F, Piccirillo M, Albino V, Palaia R, Belli A, Granata V, et al. Prospective screening increases the detection of potentially curable hepatocellular carcinoma: results in 8,900 high-risk patients. HPB (Oxford). 2013;15:985-90. [PMID: 23607636]
48. Cottone M, Virdone R, Fusco G, Orlando A, Turri M, Caltagirone M, et al. Asymptomatic hepatocellular carcinoma in Child's A cirrhosis. A comparison of natural history and surgical treatment. Gastroenterology. 1989;96:1566-71. [PMID: 2469617]
49. Ebara M, Ohto M, Shinagawa T, Sugiura N, Kimura K, Matsutani S, et al. Natural history of minute hepatocellular carcinoma smaller than three centimeters complicating cirrhosis. A study in 22 patients. Gastroenterology. 1986;90: 289-98. [PMID: 2416627]
50. Sheu JC, Sung JL, Chen DS, Yang PM, Lai MY, Lee CS, et al. Growth rate of asymptomatic hepatocellular carcinoma and its clinical implications. Gastroenterology. 1985;89:259-66. [PMID: 2408960]
51. Barbara L, Benzi G, Gaiani S, Fusconi F, Zironi G, Siringo S, et al. Natural history of small untreated hepatocellular carcinoma in cirrhosis: a multivariate analysis of prognostic factors of tumor growth rate and patient survival. Hepatology. 1992;16:132-7. [PMID: 1352268]
52. Schlansky B, Chen Y, Austin D, Naugler WE. Wait list time predicts survival after liver transplantation for hepatocellular carcinoma: a cohort study in the UNOS registry. Hepatology. 2013;58:208A.
53. Llovet JM, Bustamante J, Castells A, Vilana R, Ayuso Mdel C, Sala M, et al. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology. 1999;29:62-7. [PMID: 9862851]
54. Singal AG, Pillai A, Tiro J. Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a metaanalysis. PLoS Med. 2014;11:e1001624. [PMID: 24691105]
55. Cucchetti A, Cescon M, Erroi V, Pinna AD. Cost-effectiveness of liver cancer screening. Best Pract Res Clin Gastroenterol. 2013;27:961-72. [PMID: 24182614]
56. Guyatt GH, Norris SL, Schulman S, Hirsh J, Eckman MH, Akl EA, et al; American College of Chest Physicians. Methodology for the development of antithrombotic therapy and prevention of thrombosis guidelines: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:53S-70S. [PMID: 22315256]
57. Moher D, Pham B, Lawson ML, Klassen TP. The inclusion of reports of randomised trials published in languages other than English in systematic reviews. Health Technol Assess. 2003;7:1-90. [PMID: 14670218]